The Ypsomed Group is a leading Swiss developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injection pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife™ Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 1700 employees.

About Uni-Bio Science Group

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com^[1]

About Uni-E4

Uni-E4, a GLP-1 agonist, is a non-insulin treatment candidate that stimulates the incretin pathway and is effective in the treatment of Type 2 diabetes. GLP-1 agonist is also one of the only classes of diabetic drugs shown to also cause weight loss. As obesity is a common comorbidity of T2DM, this class is effective in T2DM patients who are overweight, accounting for at least 30% of all diabetes patients in the PRC according to IMS primary research. Moreover, this class of drugs also has other beneficial effects that are expected to drive physician prescription, such as lowering the risk of hypoglycemia and promoting β-cell regeneration, important clinical advantages in managing Type 2 diabetes complications in the long term.

About Uni-PTH

Uni-PTH (Parathyroid hormone 1-34 analogue or rhPTH (1-34)) is an effective agent treating osteoporosis and ostealgia. It is a Class VII prescription new drug and is the world's only anabolic (bone growing) agent. Uni-PTH has the potential to offer patients in China an affordable and effective treatment option for osteoporosis and ostealgia compared to current treatment options. Currently, the PRC osteoporosis market is expected to be worth RMB 15.5 billion (approximately one fifth of the global osteoporosis market) and will continue to grow quickly largely due to increasing prevalence of osteoporosis among the female and elderly population, rising standards of living and increasing awareness and education in bone health.

References

1. ^{^} www.uni-bioscience.com (www.uni-bioscience.com)